9.60Open9.60Pre Close0 Volume5 Open Interest125.00Strike Price0.00Turnover2180.22%IV6.58%PremiumMay 2, 2025Expiry Date1.47Intrinsic Value100Multiplier0DDays to Expiry8.13Extrinsic Value100Contract SizeAmericanOptions Type-0.6865Delta0.1169Gamma58.13Leverage Ratio-1183.4397Theta0.0000Rho-39.91Eff Leverage0.0005Vega
Biogen Stock Discussion
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
No comment yet